{"url_path":"/sec/clpt/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1285550/0001193125-26-221890-index.html","accession_number":"0001193125-26-221890","cik":"0001285550","ticker":"CLPT","issuer_name":"ClearPoint Neuro, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1285550/0001193125-26-221890-index.html","primary_entity_key":"0001285550","primary_entity_name":"ClearPoint Neuro, Inc."},"word_count":1133,"has_tables":true,"body_markdown":"10-Q\n\nfalse0001285550Q1--12-3111P1Y1thirty-six monthshttp://fasb.org/srt/2025#ChiefExecutiveOfficerMember0001285550clpt:EmployeeStockPurchasePlanMember2026-03-310001285550clpt:NeurosurgeryNavigationAndTherapyMember2026-01-012026-03-310001285550clpt:IRRASHoldingsIncMemberus-gaap:CommonStockMember2025-11-202025-11-200001285550clpt:LifeScienceBuildingSanDiegoCaliforniaMember2026-03-310001285550clpt:IRRASHoldingsIncMemberclpt:FormerEquityHoldersMember2025-11-202025-11-200001285550us-gaap:AdditionalPaidInCapitalMember2025-12-310001285550srt:MaximumMember2026-03-310001285550us-gaap:RestrictedStockMember2025-01-012025-03-310001285550us-gaap:RelatedPartyMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-03-310001285550srt:MinimumMember2026-03-310001285550clpt:SecondSaleOfPrincipalAmountOfNotesMemberclpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMemberclpt:IncrementTwoMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-05-120001285550clpt:CapitalEquipmentAndSoftwareServicesMember2025-01-012025-03-310001285550us-gaap:DevelopedTechnologyRightsMember2026-01-012026-03-310001285550clpt:SecondSaleOrThirdSaleOfNotesMemberclpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-05-122025-05-120001285550clpt:AtTheMarketEquityOfferingMember2026-03-310001285550clpt:PhaseOneMemberclpt:LifeScienceBuildingSanDiegoCaliforniaMember2025-06-160001285550us-gaap:TrademarksAndTradeNamesMemberus-gaap:SellingAndMarketingExpenseMember2025-01-012025-03-310001285550us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001285550clpt:BiologicsAndDrugDeliveryMember2025-01-012025-03-310001285550us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001285550us-gaap:SellingAndMarketingExpenseMember2026-01-012026-03-310001285550clpt:IRRASHoldingsIncMember2026-03-3100012855502025-01-012025-03-310001285550us-gaap:CustomerRelationshipsMember2026-03-310001285550clpt:CommonStockSubscriptionsMember2026-03-310001285550clpt:AtTheMarketEquityOfferingMember2024-11-012024-11-300001285550clpt:CapitalEquipmentAndSoftwareMember2026-01-012026-03-3100012855502025-01-012025-12-310001285550us-gaap:AdditionalPaidInCapitalMember2026-03-3100012855502024-12-310001285550clpt:SecondSaleOfPrincipalAmountOfNotesMemberclpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-05-120001285550clpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2026-01-012026-03-310001285550clpt:AfterTheFirstAnniversaryAndPriorToTheSecondAnniversaryOfDebtRedemptionMemberclpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMember2025-05-122025-05-120001285550clpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-05-120001285550us-gaap:RestrictedStockUnitsRSUMember2025-12-310001285550us-gaap:CustomerRelationshipsMember2026-01-012026-03-310001285550srt:MinimumMemberclpt:LeasedOfficeAndManufacturingFacilityMember2026-03-3100012855502025-06-162025-06-160001285550us-gaap:CommonStockMember2024-12-310001285550us-gaap:AdditionalPaidInCapitalMember2025-03-310001285550clpt:OfficeLeaseSolanaBeachCaliforniaMember2026-03-310001285550clpt:TwoThousandTwentyFiveStockPurchaseAgreementMemberclpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMember2025-05-1200012855502026-03-310001285550clpt:CapitalEquipmentAndSoftwareRelatedServiceMember2026-03-310001285550clpt:IRRASHoldingsIncMember2025-11-202025-11-200001285550clpt:SecondSaleOfPrincipalAmountOfNotesMemberclpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMemberclpt:IncrementOneMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-05-120001285550clpt:IRRASHoldingsIncMember2026-01-012026-03-310001285550clpt:AfterTheSecondAnniversaryAndPriorToTheThirdAnniversaryOfDebtRedemptionMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-05-122025-05-120001285550clpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-05-122025-05-120001285550clpt:AfterTheFourthAnniversaryAndPriorToTheSixthAnniversaryOfDebtRedemptionMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-05-122025-05-120001285550clpt:TwoThousandTwentyFiveStockPurchaseAgreementMemberclpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMember2025-05-012025-05-310001285550srt:MinimumMember2026-01-012026-03-310001285550clpt:ThirdSaleOfPrincipalAmountOfNotesMemberclpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-05-120001285550clpt:ThirdSaleOfPrincipalAmountOfNotesMemberclpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-05-122025-05-1200012855502026-04-01clpt:CapitalEquipmentAndSoftwareRelatedServiceMember2026-03-310001285550us-gaap:ServiceMember2025-01-012025-03-310001285550us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001285550us-gaap:CommonStockMember2026-01-012026-03-310001285550us-gaap:SellingAndMarketingExpenseMemberus-gaap:CustomerRelationshipsMember2026-01-012026-03-310001285550clpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMemberclpt:InitialSaleOfPrincipalAmountOfNotesMember2025-05-120001285550us-gaap:CommonStockMember2026-03-310001285550clpt:LifeScienceBuildingSanDiegoCaliforniaMember2025-06-160001285550us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001285550clpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-05-310001285550srt:MaximumMember2026-01-012026-03-310001285550clpt:ThirdSaleOfPrincipalAmountOfNotesMemberclpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-11-200001285550clpt:NeurosurgeryNavigationAndTherapyDisposableProductsMember2025-01-012025-03-310001285550us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001285550clpt:BiologicsAndDrugDeliveryDisposableProductsMember2026-01-012026-03-310001285550us-gaap:ProductMember2025-01-012025-03-310001285550us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001285550clpt:NeurosurgeryNavigationAndTherapyMember2025-01-012025-03-310001285550us-gaap:RelatedPartyMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-03-310001285550srt:MinimumMemberclpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-05-122025-05-120001285550us-gaap:CommonStockMember2025-12-310001285550us-gaap:SellingAndMarketingExpenseMemberus-gaap:CustomerRelationshipsMember2025-01-012025-03-310001285550clpt:NoCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-03-310001285550clpt:SixthAmendedAndRestated2013IncentiveCompensationPlanMember2025-05-310001285550us-gaap:DevelopedTechnologyRightsMemberus-gaap:CostOfSalesMember2025-01-012025-03-310001285550clpt:NotesMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2026-03-310001285550srt:MaximumMemberclpt:LeasedOfficeAndManufacturingFacilityMember2026-03-310001285550clpt:CapitalEquipmentAndSoftwareRelatedServiceMember2025-01-012025-03-310001285550clpt:BeforeTheFirstAnniversaryOfDebtRedemptionMemberclpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMember2025-05-122025-05-120001285550us-gaap:CostOfSalesMember2026-01-012026-03-3100012855502025-12-310001285550us-gaap:DevelopedTechnologyRightsMemberus-gaap:CostOfSalesMember2026-01-012026-03-310001285550us-gaap:ServiceMember2026-01-012026-03-310001285550clpt:CapitalEquipmentAndSoftwareServicesMember2026-01-012026-03-310001285550us-gaap:RetainedEarningsMember2026-01-012026-03-310001285550us-gaap:EmployeeStockMember2026-01-012026-03-310001285550us-gaap:TrademarksAndTradeNamesMember2026-01-012026-03-310001285550us-gaap:CommonStockMember2025-03-310001285550clpt:PhaseTwoMemberclpt:LifeScienceBuildingSanDiegoCaliforniaMember2025-06-160001285550us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberclpt:AdditionalCustomer1Member2025-01-012025-03-310001285550clpt:NoCustomersMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-12-310001285550clpt:LifeScienceBuildingSanDiegoCaliforniaMember2026-01-012026-03-310001285550us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001285550clpt:LeasedOfficeAndManufacturingFacilityMember2026-03-310001285550us-gaap:RetainedEarningsMember2025-12-310001285550clpt:CommonStockSubscriptionsMember2026-01-012026-03-310001285550clpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-11-202025-11-2000012855502026-01-012026-03-310001285550us-gaap:SellingAndMarketingExpenseMember2025-01-012025-03-310001285550us-gaap:RestrictedStockMember2026-01-012026-03-310001285550us-gaap:CommonStockMember2025-01-012025-03-310001285550us-gaap:RetainedEarningsMember2025-01-012025-03-310001285550us-gaap:EmployeeStockMember2025-01-012025-03-310001285550us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001285550srt:MinimumMemberclpt:EmployeeStockPurchasePlanMember2021-06-030001285550us-gaap:DevelopedTechnologyRightsMember2026-03-310001285550clpt:CapitalEquipmentAndSoftwareRelatedServiceMember2026-01-012026-03-310001285550us-gaap:RetainedEarningsMember2026-03-310001285550clpt:SecondSaleOfPrincipalAmountOfNotesMemberclpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMembersrt:MaximumMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-05-122025-05-120001285550clpt:BiologicsAndDrugDeliveryServicesAndLicenseFeesMember2026-01-012026-03-310001285550clpt:EmployeeStockPurchasePlanMembersrt:MaximumMember2021-06-030001285550clpt:NeurosurgeryNavigationAndTherapyDisposableProductsMember2026-01-012026-03-310001285550us-gaap:AdditionalPaidInCapitalMember2024-12-310001285550clpt:BiologicsAndDrugDeliveryMember2026-01-012026-03-310001285550clpt:BiologicsAndDrugDeliveryDisposableProductsMember2025-01-012025-03-310001285550us-gaap:TrademarksAndTradeNamesMember2026-03-310001285550clpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMembersrt:MaximumMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-05-120001285550us-gaap:CostOfSalesMember2025-01-012025-03-310001285550clpt:LifeScienceBuildingSanDiegoCaliforniaMember2025-06-162025-06-1600012855502025-03-310001285550us-gaap:RestrictedStockUnitsRSUMember2026-03-310001285550clpt:PhaseThreeMemberclpt:LifeScienceBuildingSanDiegoCaliforniaMember2025-06-160001285550us-gaap:RetainedEarningsMember2024-12-310001285550us-gaap:ProductMember2026-01-012026-03-310001285550clpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMemberclpt:AfterTheThirdAnniversaryAndPriorToTheFourthAnniversaryOfDebtRedemptionMember2025-05-122025-05-1200012855502026-05-070001285550clpt:IRRASHoldingsIncMemberclpt:FormerEquityHoldersMember2026-03-310001285550clpt:CapitalEquipmentAndSoftwareMember2025-01-012025-03-310001285550us-gaap:RetainedEarningsMember2025-03-310001285550us-gaap:TrademarksAndTradeNamesMemberus-gaap:SellingAndMarketingExpenseMember2026-01-012026-03-310001285550clpt:CapitalEquipmentAndSoftwareSystemsAndSoftwareProductsMember2026-01-012026-03-310001285550clpt:SixthAnniversaryOfDebtRedemptionMemberclpt:TwoThousandTwentyFiveNotePurchaseAgreementMember2025-05-122025-05-120001285550clpt:CommonStockSubscriptionsMember2025-12-310001285550clpt:BiologicsAndDrugDeliveryServicesAndLicenseFeesMember2025-01-012025-03-310001285550clpt:CapitalEquipmentAndSoftwareSystemsAndSoftwareProductsMember2025-01-012025-03-310001285550us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001285550clpt:TwoThousandTwentyFiveStockPurchaseAgreementMemberclpt:TPCInvestmentsIIILPAffiliateOfOberlandCapitalManagementLLCMember2025-05-122025-05-12clpt:Customerclpt:OptionToExtendxbrli:pureutr:sqftxbrli:sharesclpt:Incrementclpt:Segmentiso4217:USDiso4217:USDxbrli:shares\n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\nFORM 10-Q\n\n(Mark One)\n\nþ\n\nQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\n \n\n \n\nFor the quarterly period ended March 31, 2026\n\n \n\n \n\nOr\n\n \n\n \n\no\n\nTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\n\n \n\n \n\n \n\nFor the transition period from_____to _____\n\nCommission file number: 001-34822\n\nClearPoint Neuro, Inc.\n\n(Exact Name of Registrant as Specified in Its Charter)\n\nDelaware\n\n58-2394628\n\n(State or Other Jurisdiction\n\n(IRS Employer\n\nof Incorporation or Organization)\n\nIdentification Number)\n\n \n\n120 S. Sierra Ave., Suite 100\n\nSolana Beach, California\n\n92075\n\n(Address of Principal Executive Offices)\n\n(Zip Code)\n\n(888) 287-9109\n\n(Registrant’s Telephone Number, Including Area Code)\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\nTitle of each class\n\nTrading Symbol(s)\n\nName of each exchange on which registered\n\nCommon Stock, $0.01 par value per share\n\nCLPT\n\nNasdaq Capital Market\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. þ Yes o No\n\n \n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) þ Yes o No\n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\nLarge accelerated filer o\n\nAccelerated filer ☐\n\nNon-accelerated filer þ\n\nSmaller reporting company þ\n\n \n\nEmerging growth company o\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o\n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes þ No\n\nAs of May 7, 2026, there were 29,989,563 shares of common stock outstanding.\n\n \n\n \n\n \n\n \n\nCLEARPOINT NEURO, INC.\n\nTABLE OF CONTENTS\n\n \n\n \n\nPage\n\nNumber\n\n[PART I – FINANCIAL INFORMATION](#financialinformation)\n\n1\n\n \n\n \n\n \n\n[Item 1.](#financialstatements)\n\n[Financial Statements (unaudited)](#financialstatements)\n\n1\n\n \n\n[Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025](#balancesheet)\n\n1\n\n \n\n[Condensed Consolidated Statements of Operations for the three months ended](#section8)[March 31, 2026](#balancesheet)[and 202](#section8)[5](#section8)\n\n2\n\n \n\n[Condensed Consolidated Statements of Stockholders’ Equity for the three](#section9)[months ended](#section9)[March 31, 2026](#balancesheet)[and 2025](#section9)\n\n3\n\n \n\n[Condensed Consolidated Statements of Cash Flows for the](#section10)[three](#section10)[months ended](#section10)[March 31, 2026](#balancesheet)[and 202](#section10)[5](#section10)\n\n4\n\n \n\n[Notes to Condensed Consolidated Financial Statements](#notes)\n\n6\n\n[Item 2.](#section20)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations](#section20)\n\n22\n\n[Item 3.](#section28)\n\n[Quantitative and Qualitative Disclosures About Market Risk](#section28)\n\n29\n\n[Item 4.](#section29)\n\n[Controls and Procedures](#section29)\n\n29\n\n \n\n \n\n \n\n[PART II – OTHER INFORMATION](#partii)\n\n \n\n \n\n \n\n \n\n[Item 1.](#section31)\n\n[Legal Proceedings](#section31)\n\n29\n\n[Item 1A.](#section32)\n\n[Risk Factors](#section32)\n\n29\n\n[Item 2.](#section33)\n\n[Unregistered Sales of Equity Securities and Use of Proceeds](#section33)\n\n30\n\n[Item 3.](#section34)\n\n[Defaults Upon Senior Securities](#section34)\n\n30\n\n[Item 4.](#section35)\n\n[Mine Safety Disclosures](#section35)\n\n30\n\n[Item 5.](#section36)\n\n[Other Information](#section36)\n\n30\n\n[Item 6.](#section37)\n\n[Exhibits](#section37)\n\n31\n\n \n\n \n\n \n\n[SIGNATURES](#section38)\n\n32\n\n \n\n \n\n \n\nTrademarks, Trade Names and Service Marks\n\nClearPoint Neuro®, ClearPoint®, SmartFlow®, SmartFrame®, SmartGrid®, Inflexion®, ClearPoint Maestro®, SmartFrame Array®, SmartFrame OR®, ClearPoint Neuro Orchestra®, ClearPoint Prism®, ClearPointer®, When Your Path is Unclear, We Point The Way®, ClearPoint Advanced Laboratories™, IRRAS®, and IRRAFLOW® are all trademarks of ClearPoint Neuro, Inc. and its affiliates. Any other trademarks, trade names or service marks referred to in this Quarterly Report on Form 10-Q (this “Quarterly Report”) are the property of their respective owners.\n\n \n\n \n\n \n\n \n\nSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS\n\nThis Quarterly Report on Form 10-Q contains “forward-looking statements” as defined under the U.S. federal securities laws. All statements, other than statements of historical fact, in this Quarterly Report, including statements relating to our expectations for performance, revenues and costs, and the adequacy of cash and cash equivalent balances to support operations and meet future obligations, are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements, expressed or implied by the forward-looking statements.\n\nIn some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” and similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these words. We caution you that the forward-looking statements in this Quarterly Report are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.\n\nIn evaluating forward-looking statements, you should refer to: (i) the section titled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which we filed with the United States Securities and Exchange Commission (“SEC”) on March 17, 2026 (the “2025 Form 10-K”); (ii) Item 2 of this Quarterly Report, under the heading “Management's Discussion and Analysis of Financial Condition and Results of Operations -- Factors Which May Influence Future Results of Operations;” and (iii) Part II, Item 1.A of this Quarterly Report. As a result of these risk factors, we cannot assure you that the forward-looking statements in this Quarterly Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We do not undertake to update any of the forward-looking statements after the date of this Quarterly Report, except to the extent required by applicable securities laws.\n\n \n\n \n\nPART I – FINANCIAL INFORMATION"}